drugset / Trial / NCT00474409

A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

NCT00474409 ↗

Phase 4 Withdrawn Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.

Timeline

Start
2007-05
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “Due to poor enrollment, this study was withdrawn/ terminated.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BETAHISTINE MESILATE Unknown — —

Indications